Completed NA INTERVENTIONAL NCT00002279

A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)

Dideoxycytidine (Ro 24-2027). An Open-Label, Safety Study of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine (AZT) Therapy

Sponsor: Hoffmann-La Roche

Conditions HIV Infections

Interventions Zalcitabine

Updated 5 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002279, this NA trial focuses on HIV Infections and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nutley, United States